A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer

Study Status

Open to Enrollment

Study Description

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant prostate cancer.

This research is being done because the standard treatments for metastatic prostate cancer that is growing despite medical or surgical therapies are not curative. Existing treatments, such as the docetaxel used as part of this study, may work temporarily, but unfortunately the cancer continues to grow. This test drug, 177Lu-J591, is designed to seek out prostate cancer cells and deliver a lethal dose of radiation to the areas of cancer, but not to normal areas. Some of the normal organs (liver, kidney and bone marrow) do receive some radiation dose that is within the acceptable limits.

Disease Status and/or Stage

Metastatic Prostate Cancer


Weill Cornell Medical College

Key Eligibility

  • Men age 18 and older
  • Medically or surgically castrated
  • Progressive metastatic prostate cancer despite adequate medical or surgical castration therapy
  • Must have had one but not more than 2 cytoxic chemotherapy regimens for metastatic castration-resistant prostate cancer, and at least 1 of those regimens must have contained docetaxel
  • Additional eligibility criteria discussed when you contact the study team

Principal Investigator

Scott Tagawa, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page